AOD-9604
hGH Lipolytic C-Terminal Fragment
Modified 16-residue C-terminal fragment of human growth hormone (177-191), engineered to retain lipolytic activity without the metabolic effects of full-length hGH. Available in 2 mg, 5 mg, and 10 mg.
Fat Loss / Metabolic
Category
From $35.99
Price
Research
Grade
Price
From $35.99
✓ 10% off via PeptidesMuscle
Suggested Protocol
Published research cadences typically run 300mcg subcutaneously once daily, often pre-breakfast on an empty stomach (matching the original Metabolic Pharmaceuticals clinical-trial schedule). Some protocols split dosing to morning + evening to maintain circulating exposure. Cycles of 4–8 weeks are standard.
AOD-9604 is the "Anti-Obesity Drug 9604" — a 16-residue peptide consisting of the C-terminal fragment of human growth hormone (residues 176-191, Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe, with an N-terminal Tyr added to improve stability and the native disulphide bridge preserved). It was developed by Frank Ng and colleagues at Monash University / Metabolic Pharmaceuticals in the late 1990s and early 2000s. The molecular rationale was to dissociate hGH's lipolytic tail (the C-terminus, which activates β3-adrenergic-like lipolytic signalling in adipocytes) from the N-terminal receptor-binding region that drives IGF-1 elevation and insulin-resistance effects.
Available Sizes
Specifications
| Product | AOD-9604 |
|---|---|
| Category | Fat Loss / Metabolic |
| Format | Lyophilized powder |
| Price | From $35.99 |
Reported Endpoints
Modified hGH C-terminal fragment (residues 176-191)
Monash University / Frank Ng / Metabolic Pharmaceuticals lineage
Designed to dissociate lipolytic from IGF-1 effects
Completed phase 2 obesity trials — modest efficacy
2mg pilot vial for short-arc or validation research
Matches ~300mcg/day published dosing for one week
Pairs Well With
Ready to start?
From $35.99
✓ 10% off via PeptidesMuscle
Administration Outline
Published research cadences typically run 300mcg subcutaneously once daily, often pre-breakfast on an empty stomach (matching the original Metabolic Pharmaceuticals clinical-trial schedule). Some protocols split dosing to morning + evening to maintain circulating exposure. Cycles of 4–8 weeks are standard.
AOD-9604 — FAQs
More in Fat Loss / Metabolic
View All
L-Carnitine
Quaternary ammonium compound required for long-chain fatty-acid transport into mitochondria. Available in two concentrations and a 5-pack.
